Development of an Advanced Manufacturing Technology for Continuous Drug Substance Production
Industrial & Engineering Chemistry Research · 28.01.2026 · 65 (3) · 1469-1482
DOI: 10.1021/acs.iecr.5c04185 ↗Kurz gefasst
Fachartikel in der Zeitschrift Industrial & Engineering Chemistry Research, online erschienen am 13.01.2026. Verfasst von Daniel G Gregory und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Life Science Engineering, Virginia Commonwealth University, 601 West Main St., Richmond, Virginia 23284, United States. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defense Advanced Research Projects Agency, U.S. Food and Drug Administration.
Abstract (Originalsprache)
We describe the early conceptual development of a candidate advanced manufacturing technology (AMT) which enables the synthesis of albuterol sulfate, a bronchodilator used for the treatment of asthma, and an API currently listed on the FDA's drug shortage list. The candidate AMT system is currently under construction for the automated production of +2,000 mg/h of albuterol sulfate via a new synthetic pathway with a 78.4% solution yield when operating at a 1.0 mL/min flow rate basis. Additionally, system throughput can be scaled 10-fold with minor modifications. The authors plan to apply for AMT approval of this technology under the FDA's new AMT designation program. Key engineering design strategies are highlighted for successful translation of traditional batch synthetic methods toward continuous manufacturing, with an emphasis placed on process intensification via rational synthon selection, the introduction of continuous flow technologies, incorporation of in-line process analytical technologies (PAT), and system scale-up within a larger production facility. Analytical characterization via high-performance liquid chromatography (HPLC), LC mass spectrometry (LC-MS), gas chromatography-flame ionization detection (GC-FID), and in-line nuclear magnetic resonance spectroscopy (NMR) are utilized to assess composition and purity throughout the process. The results presented herein enable scale-up of an automated continuous manufacturing system as it provides a means of exceeding batch efficiency during the production of liquid drug formulations; a strategy which can reduce capital costs, eliminate drug shortages, and strengthen America's pharmaceutical supply chain resiliency.
Autor:innen und Institutionen
- Department of Chemical and Life Science Engineering, Virginia Commonwealth University, 601 West Main St., Richmond, Virginia 23284, United States.
ORCID-Profile: Daniel G Gregory, James K Ferri
Förderung
- Defense Advanced Research Projects Agency
- U.S. Food and Drug Administration
Zitieren
APA
Gregory, D. G., Kay, K. E., Turnage, J. T., Penzer, K. E., & Ferri, J. K. (2026). Development of an Advanced Manufacturing Technology for Continuous Drug Substance Production. Industrial & Engineering Chemistry Research, 65(3), 1469-1482. https://doi.org/10.1021/acs.iecr.5c04185
Vancouver
Gregory DG, Kay KE, Turnage JT, Penzer KE, Ferri JK. Development of an Advanced Manufacturing Technology for Continuous Drug Substance Production. Industrial & Engineering Chemistry Research. 2026;65(3):1469-1482. doi:10.1021/acs.iecr.5c04185
BibTeX
@article{Gregory2026,
author = {Gregory, Daniel G and Kay, Kaitlin E and Turnage, Justin T and Penzer, Kimberly E and Ferri, James K},
title = {Development of an Advanced Manufacturing Technology for Continuous Drug Substance Production},
journal = {Industrial & Engineering Chemistry Research},
year = {2026},
volume = {65},
number = {3},
pages = {1469--1482},
doi = {10.1021/acs.iecr.5c04185}
}
EUVIMED